Top Markets
Coin of the day
Myovant Sciences Ltd. Myovant Sciences Ltd.

Myovant Sciences Ltd.

MYOV
Rankning i aktier #5521
Myovant Sciences Ltd. is a biopharmaceutical company focused on innovating... Myovant Sciences Ltd. is a biopharmaceutical company focused on innovating healthcare solutions for both women and men. Its flagship product is relugolix, an orally administered, once-daily small molecule that functions as a gonadotropin-releasing hormone (GnRH) receptor antagonist. This medication is indicated for conditions such as heavy menstrual bleeding caused by uterine fibroids, pain associated with endometriosis, and advanced prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin agonist, currently in Phase II clinical trials for treating female infertility within assisted reproductive procedures. Myovant collaborates with Pfizer Inc. for the development and commercialization of relugolix across oncology and women's health sectors. Incorporated in 2016, initially as Roivant Endocrinology Ltd. before rebranding to Myovant Sciences Ltd. in May of that year, the firm is based in London, United Kingdom, and operates as a subsidiary of Sumitovant Biopharma Ltd.
Aktiekurs
$26.98
Senast synkroniserad: 2023-03-09
Marknadsvärde
$2.62B
Förändring (1 dag)
-0.04%
Förändring (1 år)
0.00%
Land
GB
Handel Myovant Sciences Ltd. (MYOV)

Kategori

Aktiekurshistorik för Myovant Sciences Ltd. (MYOV)
Högsta slutkurs: $26.97 den 2023-03-01

Lägsta slutkurs: $12.79 den 2016-10-01
Aktiekurshistorik för Myovant Sciences Ltd. från 2016 till 2026
Årlig aktiekursutveckling
År Prestanda
2023 0.28%
2022 73.07%
2021 -37.07%
2020 50.47%
2019 -4.83%
2018 41.15%
2017 8.58%
2016 0.00%
Aktiekurs för liknande företag eller konkurrenter
Företag Aktiekurs Förändring 1år% Land
$549.38 41.20%
US
$1.05K 47.75%
NL
$148.35 491.02%
US
$122.63 -12.65%
AU
$762.91 6.87%
CH